ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
DNA 복구 약물 시장 규모는 최근 빠르게 확대하고 있습니다. 2025년 130억 달러에서 2026년에는 155억 5,000만 달러로, CAGR 19.6%로 성장할 것으로 예상됩니다. 지난 수년간의 성장에는 전 세계 암 발생률 증가, 화학요법 및 방사선 치료의 채택 증가, PARP 억제제의 임상적 성공, 종양학 분야의 의약품 승인 증가, 병원 기반 암 치료 인프라 확대 등이 주요 요인으로 작용한 것으로 보입니다.
DNA 복구 약물 시장 규모는 향후 몇 년간 급속한 성장이 전망됩니다. 2030년에는 322억 1,000만 달러에 달하고, CAGR은 20.0%가 될 전망입니다. 예측 기간의 성장 요인으로는 정밀의료 도입 확대, DNA 손상 반응 조사에 대한 투자 증가, 암 유지요법에 대한 수요 증가, 표적형 암 치료 파이프라인 확대, 유전자 변이 진단 식별 정확도 향상 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 PARP 억제제 기반 치료법의 확대, 병용 암 치료의 이용 증가, 맞춤 암 치료제에 대한 관심 증가, 유지 요법의 적용 확대, 차세대 DDR 억제제의 발전 등을 꼽을 수 있습니다.
암 발병률의 증가는 향후 몇 년 동안 DNA 복구제 시장의 확대를 촉진할 것으로 예상됩니다. 암은 비정상적인 세포가 통제할 수 없을 정도로 증식하여 정상 경계를 넘어 확대되고, 다른 장기로 전이되거나 주변 조직으로 침윤하여 거의 모든 장기나 조직에 발생할 수 있는 질환군입니다. 암 발생률의 증가는 흡연, 방사선 노출, 발암물질, 비만, 유전자 변이 등의 요인에 기인합니다. DNA 복구제는 암세포가 손상된 DNA를 복구하는 능력을 억제하여 암세포의 추가 복제를 막고 암세포 사멸을 유도하는 작용을 합니다. 예를 들어, 호주 정부 기관인 호주 보건 복지 연구소(AIHW)에 따르면, 2024년 7월 기준 호주 내 암 진단 건수는 2022년 16,570건에서 2023년 16만 4,694건으로 증가하여 전년 대비 큰 폭의 상승세를 보이고 있습니다. 그 결과, 암 부담의 증가가 DNA 복구제 시장의 성장에 기여하고 있습니다.
DNA 복구제 시장에서 사업을 전개하는 주요 기업들은 경구용 폴리 ADP 리보스 중합효소(PARP) 억제제 등 혁신적인 치료법 개발에 주력하고 있습니다. 경구용 PARP 억제제는 DNA 복구 메커니즘에 관여하는 PARP 효소를 특이적으로 표적으로 하는 경구용 약물입니다. 예를 들어, 2023년 6월, 미국에 본사를 둔 세계 제약사 화이자는 탈제나(TALZENNA, 타라조파립)에 대한 미국 식품의약국(FDA)의 승인을 획득했다고 발표했습니다. 타라조파립은 상동 재조합 복구 유전자 변이가 있는 전이성 거세 저항성 전립선암 성인 환자에게 기존 표준치료제인 에탄드리브(XTANDI)와 병용요법으로 승인된 세계 최초의 PARP 억제제입니다. 타라조파립은 PARP 효소 활성을 억제하고, DNA 손상 부위에 PARP를 포획하여 암세포의 증식을 억제하고 세포 사멸을 유도하는 작용을 합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 시장에서 세계의 총 잠재 시장 규모(TAM)
제9장 시장 세분화
제10장 지역별, 국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자 환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업과 혁신적 기업
제38장 세계의 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
KSM
영문 목차
영문목차
DNA repair drugs are therapeutic agents developed to support or restore the body's natural DNA repair mechanisms within cells. These drugs are used in the treatment of various conditions, including cancer, by helping repair genetic damage and enhancing the effectiveness of other therapies such as chemotherapy and radiation.
The main types of DNA repair drugs include olaparib, rucaparib, niraparib, talazoparib, and others. Olaparib is a medication used to treat adults with certain types of prostate cancer, pancreatic cancer, breast cancer, ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, either as a standalone therapy or in combination with other drugs. These medications are distributed through hospital pharmacies, retail pharmacies, and other channels, and are used for the treatment of ovarian cancer, fallopian tube cancer, peritoneal cancer, breast cancer, and other indications.
Tariffs have influenced the dna repair drugs market by increasing costs for imported active pharmaceutical ingredients, specialized intermediates, and advanced manufacturing equipment used in oncology drug production. These impacts are most pronounced across branded parp inhibitors, combination therapies, and hospital pharmacy distribution channels, with north america and europe particularly affected due to complex cross-border supply chains. Tariff pressures have also slowed pricing flexibility and delayed product availability in some regions. However, tariffs are encouraging localized manufacturing, regional sourcing strategies, and domestic pharmaceutical investments, which may strengthen long-term supply resilience and innovation capacity.
The dna repair drugs market research report is one of a series of new reports from The Business Research Company that provides dna repair drugs market statistics, including dna repair drugs industry global market size, regional shares, competitors with a dna repair drugs market share, detailed dna repair drugs market segments, market trends and opportunities, and any further data you may need to thrive in the dna repair drugs industry. This dna repair drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The dna repair drugs market size has grown rapidly in recent years. It will grow from $13 billion in 2025 to $15.55 billion in 2026 at a compound annual growth rate (CAGR) of 19.6%. The growth in the historic period can be attributed to rising global cancer incidence, increased adoption of chemotherapy and radiation, strong clinical success of parp inhibitors, growth in oncology drug approvals, expansion of hospital-based cancer treatment infrastructure.
The dna repair drugs market size is expected to see rapid growth in the next few years. It will grow to $32.21 billion in 2030 at a compound annual growth rate (CAGR) of 20.0%. The growth in the forecast period can be attributed to increasing precision medicine adoption, growing investment in dna damage response research, rising demand for maintenance cancer therapies, expansion of targeted oncology pipelines, improved diagnostic identification of genetic mutations. Major trends in the forecast period include expansion of parp inhibitor-based therapies, rising use of combination cancer treatments, increased focus on personalized oncology drugs, growth in maintenance therapy applications, advancements in next-generation ddr inhibitors.
The increasing prevalence of cancer is anticipated to drive the expansion of the DNA repair drug market in the coming years. Cancer is a group of diseases that can arise in almost any organ or tissue when abnormal cells grow uncontrollably, extend beyond their normal boundaries, and spread to other organs or invade nearby tissues. The rise in cancer incidence is largely attributed to factors such as smoking, radiation exposure, carcinogenic substances, obesity, and genetic mutations. DNA repair drugs work by disrupting the ability of cancer cells to repair damaged DNA, thereby preventing further replication and leading to cancer cell death. For example, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, the number of cancer cases diagnosed in Australia increased from 160,570 in 2022 to 164,694 in 2023, indicating a significant year-on-year rise. Consequently, the growing burden of cancer is contributing to the growth of the DNA repair drug market.
Major companies operating in the DNA repair drug market are concentrating on the development of innovative therapies such as oral poly ADP-ribose polymerase (PARP) inhibitors. Oral PARP inhibitors are medications administered by mouth that specifically target the PARP enzyme involved in DNA repair mechanisms. For instance, in June 2023, Pfizer Inc., a US-based global pharmaceutical company, announced approval from the U.S. Food and Drug Administration for TALZENNA (talazoparib). TALZENNA became the first and only PARP inhibitor approved for use in combination with the established standard therapy XTANDI for adult patients with metastatic castration-resistant prostate cancer carrying homologous recombination repair gene mutations. TALZENNA works by inhibiting PARP enzyme activity and trapping PARP at sites of DNA damage, which suppresses cancer cell growth and induces cell death.
In October 2024, Merck & Co. acquired Modifi Biosciences for approximately $30 million. Through this acquisition, Merck aims to strengthen its oncology pipeline by gaining access to a novel class of small-molecule therapies that exploit DNA repair deficiencies in cancer cells. Modifi Biosciences is a US-based company focused on developing DNA-modification-enabled cancer therapeutics that selectively target tumors lacking the DNA repair protein MGMT.
Major companies operating in the dna repair drugs market are Pfizer Inc., Johnson & Johnson Private Limited, AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Merck KGaA, Regeneron Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Jiangsu HengRui Medicine Co. Ltd., Genentech Inc., ClovisOncology Inc., Karyopharm Therapeutics Inc., Repare Therapeutics Inc., C4 Therapeutics Inc., Precision BioSciences, Artios Pharma Limited, FoRx Therapeutics AG, Onxeo SA
North America was the largest region in the DNA repair drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dna repair drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the dna repair drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The DNA repair drugs market consists of sales of veliparib, methyl methane sulfonate, mitomycin C, and cisplatin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
DNA Repair Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses dna repair drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for dna repair drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The dna repair drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Drug Type: Olaparib; Rucaparib; Niraparib; Talazoparib; Other Drugs
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
3) By Application: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Breast Cancer; Other Applications
Subsegments:
1) By Olaparib: Tablets; Capsules; Combination Therapies
2) By Rucaparib: Tablets; Monotherapy; Combination with Other Cancer Treatments
3) By Niraparib: Capsules; Extended-Release Formulations; Maintenance Therapy Applications
4) By Talazoparib: Capsules; Combination with Immunotherapy; High-Dose and Low-Dose Options
5) By Other Drugs: Experimental PARP Inhibitors; Generic and Biosimilar Versions; Next-Generation DNA Damage Response (DDR) Inhibitors
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.2.3 Increased Focus On Personalized Oncology Drugs
4.2.4 Growth In Maintenance Therapy Applications
4.2.5 Advancements In Next-Generation Ddr Inhibitors
5. DNA Repair Drugs Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Oncology Specialty Clinics
5.3 Cancer Research Institutes
5.4 Academic Medical Centers
5.5 Specialty Pharmacies
6. DNA Repair Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global DNA Repair Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global DNA Repair Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global DNA Repair Drugs Market Size, Comparisons And Growth Rate Analysis
7.3. Global DNA Repair Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global DNA Repair Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global DNA Repair Drugs Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. DNA Repair Drugs Market Segmentation
9.1. Global DNA Repair Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Olaparib, Rucaparib, Niraparib, Talazoparib, Other Drugs
9.2. Global DNA Repair Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
9.3. Global DNA Repair Drugs Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer, Other Applications
9.4. Global DNA Repair Drugs Market, Sub-Segmentation Of Olaparib, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Tablets, Capsules, Combination Therapies
9.5. Global DNA Repair Drugs Market, Sub-Segmentation Of Rucaparib, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Tablets, Monotherapy, Combination with Other Cancer Treatments
9.6. Global DNA Repair Drugs Market, Sub-Segmentation Of Niraparib, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.7. Global DNA Repair Drugs Market, Sub-Segmentation Of Talazoparib, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Capsules, Combination with Immunotherapy, High-Dose and Low-Dose Options
9.8. Global DNA Repair Drugs Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Experimental PARP Inhibitors, Generic and Biosimilar Versions, Next-Generation DNA Damage Response (DDR) Inhibitors
10. DNA Repair Drugs Market Regional And Country Analysis
10.1. Global DNA Repair Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global DNA Repair Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
11. Asia-Pacific DNA Repair Drugs Market
11.1. Asia-Pacific DNA Repair Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific DNA Repair Drugs Market, Segmentation By Drug Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China DNA Repair Drugs Market
12.1. China DNA Repair Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China DNA Repair Drugs Market, Segmentation By Drug Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India DNA Repair Drugs Market
13.1. India DNA Repair Drugs Market, Segmentation By Drug Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan DNA Repair Drugs Market
14.1. Japan DNA Repair Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan DNA Repair Drugs Market, Segmentation By Drug Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia DNA Repair Drugs Market
15.1. Australia DNA Repair Drugs Market, Segmentation By Drug Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia DNA Repair Drugs Market
16.1. Indonesia DNA Repair Drugs Market, Segmentation By Drug Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea DNA Repair Drugs Market
17.1. South Korea DNA Repair Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea DNA Repair Drugs Market, Segmentation By Drug Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. Taiwan DNA Repair Drugs Market
18.1. Taiwan DNA Repair Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan DNA Repair Drugs Market, Segmentation By Drug Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia DNA Repair Drugs Market
19.1. South East Asia DNA Repair Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia DNA Repair Drugs Market, Segmentation By Drug Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe DNA Repair Drugs Market
20.1. Western Europe DNA Repair Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe DNA Repair Drugs Market, Segmentation By Drug Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK DNA Repair Drugs Market
21.1. UK DNA Repair Drugs Market, Segmentation By Drug Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany DNA Repair Drugs Market
22.1. Germany DNA Repair Drugs Market, Segmentation By Drug Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France DNA Repair Drugs Market
23.1. France DNA Repair Drugs Market, Segmentation By Drug Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy DNA Repair Drugs Market
24.1. Italy DNA Repair Drugs Market, Segmentation By Drug Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain DNA Repair Drugs Market
25.1. Spain DNA Repair Drugs Market, Segmentation By Drug Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe DNA Repair Drugs Market
26.1. Eastern Europe DNA Repair Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe DNA Repair Drugs Market, Segmentation By Drug Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia DNA Repair Drugs Market
27.1. Russia DNA Repair Drugs Market, Segmentation By Drug Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America DNA Repair Drugs Market
28.1. North America DNA Repair Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America DNA Repair Drugs Market, Segmentation By Drug Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA DNA Repair Drugs Market
29.1. USA DNA Repair Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA DNA Repair Drugs Market, Segmentation By Drug Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
30. Canada DNA Repair Drugs Market
30.1. Canada DNA Repair Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada DNA Repair Drugs Market, Segmentation By Drug Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America DNA Repair Drugs Market
31.1. South America DNA Repair Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America DNA Repair Drugs Market, Segmentation By Drug Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil DNA Repair Drugs Market
32.1. Brazil DNA Repair Drugs Market, Segmentation By Drug Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East DNA Repair Drugs Market
33.1. Middle East DNA Repair Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East DNA Repair Drugs Market, Segmentation By Drug Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa DNA Repair Drugs Market
34.1. Africa DNA Repair Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa DNA Repair Drugs Market, Segmentation By Drug Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. DNA Repair Drugs Market Regulatory and Investment Landscape
36. DNA Repair Drugs Market Competitive Landscape And Company Profiles
36.1. DNA Repair Drugs Market Competitive Landscape And Market Share 2024
36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. DNA Repair Drugs Market - Company Scoring Matrix
36.2.1. Market Revenues
36.2.2. Product Innovation Score
36.2.3. Brand Recognition
36.3. DNA Repair Drugs Market Company Profiles
36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
36.3.2. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
36.3.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
36.3.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
36.3.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
37. DNA Repair Drugs Market Other Major And Innovative Companies
